Learning from failed trials in ALS

Lancet Neurology

Volumn 6, Issue 12, 2007, Pages 1034-1035

  Swash, Michael ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MINOCYCLINE; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; FORCED EXPIRATORY VOLUME; GENE MUTATION; HUMAN; LETTER; MOTOR PERFORMANCE; MUSCLE STRENGTH; NONHUMAN; PRIORITY JOURNAL; RATING SCALE;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 36148996513     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(07)70271-5     Document Type: Letter

References (9)

1. Gordon P., Moore D., Miller R., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol (2007). published online Nov 1. DOI:10.1016/S1474-4422(07)70270-3
2. De Carvalho M., Costa J., and Swash M. Clinical trials in ALS; a review of the role of clinical and neurophysiological measurements. Amyotroph Lat Scler 6 (2005) 202-212
3. DiBernardo A., and Cudkowicz M. Translating insights into effective human trials in ALS. Biochim Biophys Acta 1762 (2006) 1139-1149
4. Tu P., Robinson K., Gurney M., Trojanowski J., and Lee V. Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci USA 93 (1993) 3155-3160
5. Bradley W., Miller R., and the BDNF Study Group (phase III). Phase III trial of subcutaneous recombinant human BDNF in patients with amyotrophic lateral sclerosis. Neurology 52 (1999) 1427-1433
6. Aggarwal A., and Nicholson G. Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation. J Neurol Neurosurg Psychiatry 73 (2002) 199-201
7. Miller R., Bradley W., Cudkowicz M., et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 69 (2007) 776-784
8. Ranganathan S., Nicholl G., Henry S., et al. Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects. Amyotroph Lateral Scler (2007). published online Aug 3. DOI:10.1080/17482960701549681
9. De Carvalho M., Chio A., Dengler R., Hecht M., Weber M., and Swash M. Neurophysiology and the measurement of progression in amyotrophic lateral sclerosis: a review. Amyotroph Lat Scler 6 (2005) 17-29